会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 43. 发明授权
    • Selective serine/threonine kinase inhibitors
    • 选择性丝氨酸/苏氨酸激酶抑制剂
    • US08034821B2
    • 2011-10-11
    • US12698027
    • 2010-02-01
    • John William Taunton, Jr.Michael CohenKevan ShokatChao Zhang
    • John William Taunton, Jr.Michael CohenKevan ShokatChao Zhang
    • C07D487/04A61K31/52
    • C07D487/04
    • Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase.Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase.Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.
    • 在ATP结合位点内具有一个或多个半胱氨酸残基的蛋白激酶的抑制通过使本身或细胞或受试者中的激酶与抑制有效量的具有由两个或更多个的杂环核心结构组成的化合物接触来实现 含有至少一个氮环原子的稠环,以及能够与激酶的ATP结合位点内的半胱氨酸残基反应的亲电取代基。 优选的化合物包括具有这样的亲电子取代基的某些吡咯并嘧啶和羟吲哚,以及任选的能够与位于激酶的关守位置的苏氨酸或更小残基相互作用的芳族或杂芳族取代基。 缺乏这种半胱氨酸残基的激酶可以被改造或修饰,使得它们能够被这种化合物抑制,通过用半胱氨酸残基替换ATP结合位点内的缬氨酸或其它氨基酸残基。